We have over 70 patients on our protocol right now
Liraglutide was selected as the GLP-1 receptor agonist based on pharmacokinetic properties providing stable drug levels during extended-access sessions (Oh et al., 2023) and its widespread clinical use, enhancing the translational relevance of the present design
We identified several PCT international patent applications filed in 2023 that have not yet entered into the U.S
Your Willow doctor can help determine which treatment is right for you based on your health history and weight loss goals
Key Facts Researchers from Cedars-Sinai Medical Center examined 1 million first-time GLP-1 prescriptions in the U.S
The risk of delayed gastric emptying in patients with gastroparesis, patients with neurologic deficits, and patients with chronic kidney disease is consistent with the prior literature but has not been previously studied as an independent factor that may increase the risk of retained gastric contents concomitantly with GLP-1RA use ( In this study, most patients used dulaglutide and semaglutide (Ozempic)